When Julie Saiki was diagnosed with ulcerative colitis (UC), she was pursuing a PhD in musicology — and certainly was not planning to found a biopharmaceutical company.
However, she quickly found that standard treatments did not work for her. She is not alone in this, as 16 percent of patients with moderate-to-severe UC do not respond to first-line treatments such as corticosteroids. Eventually, her search for relief led her to indigo naturalis, a botanical extract used in traditional Chinese medicine.
As soon as I took it, my symptoms went away.
—Julie Saiki, Azora Therapeutics
Saiki asked her aunt in Japan to source the same preparation. “As soon as I took it, my symptoms went away,” Saiki told DDN. “Rectal bleeding stopped. I actually was able to taper off all other medications and stayed on it for many years for maintenance therapy.”
Rather than simply sharing her discovery with other patients, Saiki wanted to understand whether it could become a medicine that doctors could prescribe and patients could collect from a pharmacy. But there was one big problem: She wasn’t a scientist.
More than a decade later, Saiki has a PhD in Chemical and Systems Biology and is now the co-founder and Chief Strategy Officer of Azora Therapeutics, a biotech preparing its lead drug candidate, AT177, for clinical development.
From one patient's experience to a clinical study
Saiki took her story to Stanford's medical school and connected with SPARK, the university's translational medicine program. In 2011, they awarded her a $50,000 pilot grant to open an investigational new drug (IND) application and conduct a small Phase 1b study in patients with UC.
The study enrolled 11 patients, many of whom had difficult-to-treat disease. Five were dependent on corticosteroids, and five had already been advised to undergo colectomy. After eight weeks of treatment, 10 of the 11 patients achieved a clinical response and three achieved clinical remission. All showed improvements in endoscopic disease severity and quality of life.
“It was really quite a surprise as we didn't know what to expect,” Saiki said. “And that's really what inspired us to found Azora.”
The study also offered an important clue about how the botanical might work. Colon biopsies collected after treatment showed a sharp increase in activity associated with the aryl hydrocarbon receptor (AhR), while experiments in a mouse model suggested that blocking the receptor abolished the treatment's benefits.
Establishing a possible mechanism also meant the researchers could begin to move beyond the complex botanical preparation itself. “When we started Azora, we really felt strongly that we needed a controlled product that could be advanced as a drug,” Saiki said.
Turning a botanical into a drug
This eventually brought Saiki together with Matt Davidson, an immunologist who had previously founded Verrica Pharmaceuticals and helped take its lead treatment through clinical development, resulting in FDA approval.
The aryl hydrocarbon receptor is a really interesting target.
—Matt Davidson, Azora Therapeutics
Together, they focused on the AhR, a transcription factor that acts as a sensor of environmental and metabolic signals. “The aryl hydrocarbon receptor is a really interesting target,” Davidson told DDN. “It regulates a huge number of genes.”
That broad activity could be particularly relevant in UC. AhR helps regulate immune responses, including the production of inflammatory and anti-inflammatory cytokines, but it also influences the intestinal barrier. In the gut, that barrier relies on tightly connected cells to prevent microbes and other potentially harmful material from passing from the intestinal lumen into surrounding tissue. Proper functioning of this barrier is essential for overall immune response and homeostasis in the gastrointestinal tract.
That combination of effects distinguished the approach from therapies designed to block a single inflammatory pathway. “A lot of scientists in the inflammatory bowel disease space continue to recognize barrier function as being just a really important part of the pathophysiology of UC,” Saiki said. “Other mechanisms of action don't target the barrier function component of UC.”
The team eventually identified indirubin as a key component of indigo naturalis responsible for activating AhR. From there, they needed to develop a compound that could be consistently manufactured and stored, while delivering the active molecule where it was needed.
“We really had to thread a needle,” Davidson said. After working with several medicinal chemistry partners and testing multiple compounds, the researchers developed AT177, a synthetic prodrug that converts directly into indirubin within the lumen of the colon.
Keeping patients at the center
For Saiki, the company still traces back to the experience that started the research in the first place. “When I went over to the med school to share my story, it was really inspired by this feeling like, ‘Hey, it worked for me, maybe it could work for other people,’” Saiki said. “That's really always been the drive behind Azora.”
That personal connection has also influenced how the company thinks about drug development. Rather than simply pursuing an interesting biological target, Saiki and Davidson are trying to develop a treatment that could fit into the lives of people with a chronic and often unpredictable disease.
“The science can be awesome, but it really needs to fit into patients' lives and be convenient and easy for them,” Davidson said. That has meant designing an oral, locally-acting treatment that could potentially be taken once a day.
The company has since entered a new phase. Following a reverse merger, Azora is now a publicly traded company focused on advancing AT177 into clinical development. The company expects to initiate a Phase 1 clinical trial of AT177 in the first half of 2027.
What started with one person's experience of a botanical remedy has since led Saiki from a musicology PhD to medical school, through academic research and drug discovery, and finally to a company preparing to test whether that same biology can be turned into a treatment for other people struggling with UC.
This article is part of The Spin-Off, a Drug Discovery News series that follows the journey from academic discovery to biotech company. From unexpected biological insights to first-in-class therapeutic approaches, university research often lays the foundation for the next generation of medicines. The Spin-Off follows the journey beyond the lab, examining the people, technologies, and translation challenges involved in turning scientific discoveries into biotech ventures.











